GlaxoSmithKline Japan to Markey New Acute Otitis Media Drug Clavamox Dry Syrup.Tokyo, Japan, Jan 19, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ) has launched prescription drug Clavamox Dry Syrup in Japan. A penicillin antibiotic with beta-lactamase inhibitor, the new drug is indicated for the treatment of acute otitis media Acute otitis media Inflammation of the middle ear with signs of infection lasting less than three months. Mentioned in: Myringotomy and Ear Tubes acute otitis media . It can exert beneficial effects with twice-a-day dosage. Clavamox is currently approved and marketed in 18 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion